MB antibodies, primarily associated with myelin basic protein (MBP), have been extensively studied in the context of autoimmune and neurological disorders. MBP, a key structural component of the myelin sheath in the central nervous system (CNS), plays a critical role in maintaining the stability and integrity of neuronal axons. First identified in the 1960s, MBP became a focal point in multiple sclerosis (MS) research when autoantibodies targeting MBP were detected in patients, suggesting an autoimmune mechanism underlying demyelination. These antibodies are thought to contribute to myelin degradation, triggering inflammatory responses and impairing nerve signal transmission.
While MB antibodies are not exclusive to MS, their presence has been linked to disease activity and progression in some cases. However, their diagnostic specificity remains controversial due to variable detection across studies and populations. Advances in assay techniques, such as ELISA and cell-based assays, have improved detection accuracy, yet challenges persist in distinguishing pathogenic from non-pathogenic antibodies.
Recent research explores MB antibodies' roles beyond MS, including neuromyelitis optica and acute disseminated encephalomyelitis. Additionally, studies investigate their potential as biomarkers for monitoring therapeutic responses or predicting relapse. Despite progress, the exact pathogenic mechanisms and clinical utility of MB antibodies require further validation, emphasizing the need for standardized detection protocols and larger cohort studies.